Access to Nusinersen in England Update
10 June 2019
We were extremely concerned to read some of the eligibility criteria in the draft Managed Access Agreement (MAA).
We raised these concerns immediately with NICE, NHS England and Biogen.
We continue to work with MDUK, TreatSMA and clinicians to establish the next most constructive steps at what is a most delicate stage in this long, difficult and distressing process. This needs very careful thought.
We will communicate further on this as soon as possible this week.